Soffinova Partners

Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating the first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease.

Odoo SA develops and installs a suite of open source business application that help the client grow business. The company offers applications to boost sales that include customer relationship management, point of sales, quote builder, mass mailing, survey, events, community builder, lead automation, and live chat; applications to build Websites that include CMS, e-Commerce, blogs, and forum; and application to run operations that include project management, billing, accounting, warehouse management, manufacturing, and procurements. Its software is available online or on-premise. Odoo SA was formerly known as OpenERP SA. The company was founded in 2005 and is based in Ramillies, Belgium.

Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

BioSpace, Inc. operates an online community for industry news and careers for life science professionals. The company operates BioSpace.com, which provides an online job board, daily biotech news feeds, and community features that connect recruiters, job seekers, and life science professionals. Its community offers recruitment and job seeking opportunities for professionals; and accelerates communication and discovery among business and scientific leaders. The company also provides career events for life science recruiting professionals in the United States and Canada. It serves professionals in biotechnology, pharmaceuticals, medical device, diagnostic, clinical research, academic, and biomedical industries. The company is based in Englewood, Colorado with an additional office in San Francisco, California. BioSpace, Inc. is a former subsidiary of DHI Group, Inc.

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

SafeHeal SAS manufactures an anastomosis protection device, Colovac. The device protects the anastomosis by isolating it from feces and aims to minimize post operative complications, such as staple line leakage. The company was founded in 2015 and is headquartered in Paris, France.

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

EryDel S.p.A. engages in the production and commercialization of drug delivery based on the use of autologous erythrocytes. The company provides medical devices which includes red cell loader, and erykit. The company was founded in 2007 and is based in Urbino, Italy.

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

ReCor Medical has developed a unique therapeutic non-focused ultrasound system for performing renal denervation in patients with resistant hypertension. The PARADISE® technology (Percutaneous Renal Denervation System) includes a 6 French catheter with a cylindrical transducer that emits ultrasound energy circumferentially, allowing for a more efficient renal denervation procedure.

MetGen develops and produces enzymes tailored to industrial customer needs. MetZymes are enzymes belonging to the class of multicopper oxidases. These enzymes are involved in several oxidative functions and particularly in delignification. MetGen have created biological enzymes that can be added into the pulp mix to separate wood fibres more effectively before the thermo-mechanical pulping stage, radically improving the energy efficiency of the whole pulp-making process.

EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating. The company is driven by a mission to make biocatalysis the first choice for chemical process designers worldwide.

Breath Therapeutics – a Zambon Group Company is pursuing groundbreaking therapies by unleashing the true potential of inhaled drug delivery. Their approach combines novel formulations of existing drugs with cutting-edge inhalation technology for the treatment of rare respiratory diseases with high unmet medical need. They are developing drug-device combinations designed to rapidly deliver high concentrations of drugs to the site of action in the lung. Their approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety.

EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.

Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential. Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

Pyrowave Inc. develops recycling technology solutions based on the use of microwave to convert plastics into liquid products and brings plastics back to the molecular state identical to virgin materials. The company leases machines for recycling plastics; and sells liquid products and other high-value materials generated during processing. It serves municipal clients, and private recyclers and generators. Pyrowave Inc. was incorporated in 2014 and is headquartered in Oakville, Canada.

Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.

VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform, which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators. VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience. AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. AblaCare's procedure is done transvaginally, under ultrasound guidance, and does not require general anesthesia. The technique can be performed in the clinic setting using the same minimally invasive access commonly used by fertility physicians for IVF.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

SafeHeal is the first company created and incubated by MD Start, a medtech accelerator developing innovative medical devices based on inventions from physicians. It is currently funded by MD Start and Sofinnova Partners. SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition (Concours Mondial de l’Innovation - Phases 1 and 2) and of the iLab grant program, which foster talent and bring out future champions of the French economy. SafeHeal was also elected as the most promising and innovative investor conference MedTech start-up at Biovision 2016, was a finalist for the global Medtech Innovator 2016 competition. Finally, SafeHeal is a 2016 recipient of the Charles Foix grant which rewards innovations aimed at improving the quality of life of elderly people.

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.

Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

Drug discovery inspired by viruses

ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.

Inotrem S.A discovers and develops novel treatments in the field of inflammatory pathologies with a focus on critical care. Its technology includes a TREM-1 inhibitor, nangibotide (LR12), that aims to control excessive inflammation in severe sepsis patients. The company was founded in 2013 and is based in Paris, France.

WYplay SAS develops digital TV software solutions. The company provides television and home media connected platforms for markets in North America. It offers software licensing to turnkey products, media center consumer electronic (CE) devices, full-HD IPTV boxes, DVB set top boxes, connected televisions, and in-home HD multimedia-HDD products. The company also offers media management, home networking, and connectivity products, as well as connected digital media player, digital media server, CD/DVD optical drive, browser, and analog acquisition components. WYplay SAS was founded in 2006 and is based in Allauch, France.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Mainstay Medical Holdings plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, and Australia. It focuses on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat people with chronic low back pain by helping to restore control to the muscles that dynamically stabilise the lumbar spine. Mainstay Medical Holdings plc was founded in 2008 and is headquartered in Dublin, Ireland.

Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

Provide a web application filtering, authentication and intrustion prevention systems.

NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

EnvoyWorldWide, Inc. provides enterprise notification and message delivery services. Its notification services for business continuity facilitates personalized, interactive voice and text broadcasts, landline phones, faxes, email, pagers, SMS and WAP phones, PDAs, BlackBerrys, and other wireless devices. The company was formerly known as MessageBlaster.com and changed its name to EnvoyWorldWide, Inc. in September, 2000. The company was founded in 1998 and is headquartered in Bedford, Massachusetts.

They at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus and restore balance. Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo. They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Myricx Pharma Ltd provides drug discovery services that develops proprietary inhibitors of human N-myristoyltransferases. It offers myristoylation, a lipid modification that includes cancer, inflammatory conditions, epilepsy, and Alzheimer’s disease solutions. The company was incorporated in 2019 and is based in Stevenage, United Kingdom.

Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

MetGen develops and produces enzymes tailored to industrial customer needs. MetZymes are enzymes belonging to the class of multicopper oxidases. These enzymes are involved in several oxidative functions and particularly in delignification. MetGen have created biological enzymes that can be added into the pulp mix to separate wood fibres more effectively before the thermo-mechanical pulping stage, radically improving the energy efficiency of the whole pulp-making process.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands. Avantium's proprietary high-throughput technology enables a faster and more cost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development. Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields: new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent. Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business. Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.

Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

Microphyt SPAS produces and sells microalgae and other photosynthetic micro-organisms for beauty care and food complement, food, health, and energy markets. The company was incorporated in 2007 and is based in Baillargues, France.

CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

CorVent Medical is developing smart, versatile, lifesaving ventilators for critical care. The company's first product, the CorVent™ Single-Use Ventilator, was designed in partnership with Design Catapult, an industrial design firm recognized for their rapid ideation of medical and commercial products. The ventilator is currently pending Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA) for ventilators, tubing connectors and accessories, which authorizes its use for the duration of the U.S. Health and Human Services COVID-19 public health emergency declaration.

BioAmber is a private US company registered in the state of Delaware. The company, formerly known as DNP Green Technology, changed its name to BioAmber following its acquisition of its joint venture with ARD. Following the transaction, they adopted the name BioAmber, which had been used to that point by the joint venture.

Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.

SafeHeal is the first company created and incubated by MD Start, a medtech accelerator developing innovative medical devices based on inventions from physicians. It is currently funded by MD Start and Sofinnova Partners. SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition (Concours Mondial de l’Innovation - Phases 1 and 2) and of the iLab grant program, which foster talent and bring out future champions of the French economy. SafeHeal was also elected as the most promising and innovative investor conference MedTech start-up at Biovision 2016, was a finalist for the global Medtech Innovator 2016 competition. Finally, SafeHeal is a 2016 recipient of the Charles Foix grant which rewards innovations aimed at improving the quality of life of elderly people.

Artios Pharma Limited, a biotechnology company, focuses on developing cancer treatments that target DNA damage response (DDR) pathways to selectively kill cancer cells. Its product pipeline includes DNA polymerase theta (Polθ), which is involved in multiple processes associated with DNA repair; an in-licensed program that targets a protein that has been identified as a novel DNA damage response target; and a novel cancer treatment targeting DNA nucleases involved in the DDR. The company was incorporated in 2015 and is headquartered in Cambridge, United Kingdom.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Green Biologics is a revenue generating industrial biotech company based in Oxfordshire aiming to become the world's leading supplier of advanced fermentation technologies for conversion of biomass to renewable fuels and chemicals.

Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

Calliditas Therapeutics, a specialty pharmaceutical company that develops pharmaceutical products in fields of unmet medical need. Its products include Nefecon, a treatment for IgA nephropathy and Busulipo, an alternative for myeloablation prior to bone marrow transplantation. The company was founded in 1991 and is headquartered in Stockholm, Sweden.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.

Prometheus Materials develops bio-cement with zero carbon emissions to reduce the global CO2 emissions. It aims to push the world towards sustainability. The company was founded in 2021 and is based in Boulder, Colorado.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed. Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.

RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

CoEnzyme is a developer of therapies designed to treat orphan neurological disorders. The company develops a treatment to restore dysregulated CoEnzyme A metabolism through its CoEnzyme metabolism platform, enabling physicians to address the profound unmet medical needs.

MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

Intransa, Inc. provides products for video security projects. It offers VideoAppliance, which delivers ready out-of-the-box appliances that slash the installation and integration process; EnterpriseServer that delivers installer-ready servers that are tuned and optimized for demands of physical security with Microsoft Server 2008; EnterpriseStorage, which reduces the risk of lost video data; and ViewingStation for remote viewing of multiple high definition streams for video surveillance applications. It serves retail and banking, public safety, manufacturing, transportation, schools and education, gaming and hospitality, government, and health care sectors. The company offers its products through distributors. Intransa, Inc. was founded in 2001 and is headquartered in Menlo Park, California.

Biosyntia ApS operates as a biotechnology company that develops biocatalysts for the fermentation of fine chemicals. The company was incorporated in 2012 and is based in Hørsholm, Denmark.

Genespire S.R.L., a biotechnology company, develops gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. The company was founded in 2020 and is based in Milan, Italy.

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways. They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcare community, in order to improve patient care in areas of high unmet medical need. Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction. In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases.

Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.

Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.